Overweight and Obesity / Hesperidin / Cognitive Dysfunction · Interventional Study

Cognitive Effects of Hesperidin in Overweight/Obese Older Adults

ClinicalTrials.gov · August 6, 2026

Preliminary Why this matters to you Expert discussion

Early or partial results. Treat as a signal, not a conclusion.

AI Summary

This is a registry record for an actively recruiting randomized controlled trial examining whether hesperidin supplementation improves cognitive function in overweight/obese older adults over 10 weeks. No results are posted; this record documents the planned study design and primary/secondary outcome measures only.

What was studied

Interventional, Randomized, Parallel, Triple masking, Treatment purpose. Cognitive Dysfunction, Overweight and Obesity; age from 55 Years; to 75 Years. Intervention: Low-Dose Hesperidin Group; High-Dose Hesperidin Group. Compared with: Placebo Group — Placebo Comparator. n = 105. 1 site: China.

Key findings

Safety

Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.

Who this may help

Clinicians should not yet use this trial to guide practice; hesperidin's cognitive effects in this population remain unproven. Results are needed to determine whether this dietary supplement merits recommendation as a cognitive health strategy.

Plain-language summary

This is a recruiting trial registration with no posted results; the study design is sound but outcomes remain unknown and unmeasured.

Study design

As stated by the source record.

MethodsPrimary outcome measures: Change in Cognitive Function Assessed by the Mini-Mental State Examination (MMSE) (assessed at Baseline to Week 10); Change in Cognitive Function Assessed by the Montreal Cognitive Assessment (MoCA) (assessed at Baseline to Week 10); Change in Cognitive Function Assessed by the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) (assessed at Baseline to Week 10); Change in Cognitive Function Assessed by the Trail Making Test (TMT) (assessed at Baseline to Week 10); Change in Cognitive Function Assessed by the Digit Symbol Substitution Test (DSST) (asse…

DesignInterventional, Randomized, Parallel, Triple masking, Treatment purpose

PopulationCognitive Dysfunction, Overweight and Obesity; age from 55 Years; to 75 Years

Sample size105

InterventionLow-Dose Hesperidin Group; High-Dose Hesperidin Group

ComparatorPlacebo Group — Placebo Comparator

Setting1 site: China

Reported figures

Quoted from the source exactly as published.

Estimated enrollment105

Study duration10 weeks

Age range55–75 years

Primary outcome measure 1Change in Cognitive Function Assessed by the Mini-Mental State Examination (MMSE), Baseline to Week 10

Primary outcome measure 2Change in Cognitive Function Assessed by the Montreal Cognitive Assessment (MoCA), Baseline to Week 10

Primary outcome measure 3Change in Cognitive Function Assessed by the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog), Baseline to Week 10

Primary outcome measure 4Change in Cognitive Function Assessed by the Trail Making Test (TMT), Baseline to Week 10

Primary outcome measure 5Change in Cognitive Function Assessed by the Digit Symbol Substitution Test (DSST), Baseline to Week 10

Clinical bottom line

Caveats

This is a registry record; no outcome data or results are reported.
Study is still recruiting; completion date and data availability are not stated.
Phase is listed as 'NA' in the registry; study funding source and institutional approvals are not detailed here.
Secondary outcomes (gut microbiota, metabolites, mechanisms) are described but primary outcome data collection and analysis plan details are sparse.

Evidence assessment

Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.

Study design

strong

Randomized, double-blind, placebo-controlled trial with three arms.

Directness

strong

Directly measures cognitive function via validated instruments in target population.

Consistency

insufficient

No results posted; consistency cannot be assessed from registry alone.

Risk of bias

moderate

Blinding and randomization planned; conduct details and adherence monitoring not fully described.

Sample adequacy

moderate

105 participants planned; adequate for primary cognitive endpoints but secondary microbiota aims may be underpowered.

What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.

Source abstract

Registry record from ClinicalTrials.gov (NCT07750223). This is a study registration, not published results. Lead sponsor: Min Hou. Recruitment status: RECRUITING. Phase: NA. Study type: INTERVENTIONAL. Enrollment: 105 participants (ESTIMATED). Conditions: Cognitive Dysfunction, Overweight and Obesity. Interventions: DIETARY_SUPPLEMENT: Hesperidin. Primary outcome measures: Change in Cognitive Function Assessed by the Mini-Mental State Examination (MMSE) , Baseline to Week 10; Change in Cognitive Function Assessed by the Montreal Cognitive Assessment (MoCA) , Baseline to Week 10; Change in Cognitive Function Assessed by the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) , Baseline to Week 10; Change in Cognitive Function Assessed by the Trail Making Test (TMT) , Baseline to Week 10; Change in Cognitive Function Assessed by the Digit Symbol Substitution Test (DSST) , Baseline to Week 10; hange in Cognitive Function Assessed by the Wechsler Memory Scale (WMS) , Baseline to Week 10. Brief summary: A randomized, double-blind, placebo-controlled trial was designed to test whether two doses of hesperidin (a natural flavonoid from citrus fruits) improve cognitive function in overweight and obese older adults. A total of 105 participants, aged 55-75 years with a BMI ≥24 kg/m² or elevated waist circumference, will be randomly assigned to one of three 10-week treatments: placebo, low-dose hesperidin (300 mg/day), or high-dose hesperidin (600 mg/day). The primary aim is to see if hesperidin supplementation enhances cognitive performance - specifically executive function, memory, and attention - and to explore any dose-response relationship. Secondary aims include examining changes in gut microbiota composition and related metabolites, as well as exploring potential mechanisms behind any observed effects. The findings are expected to provide scientific evidence on whether hesperidin could serve as a nutritional strategy to support cognitive health in this population.

Follow from this

Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.

Overweight and ObesityMin HouHesperidinNCT07750223Cognitive Dysfunction